Bausch & Lomb Corp (BLCO) stock
Close on Nov 11, 2026Market cap $7.62BP/E –Yield –
Bausch & Lomb Corp grew revenue 8.9% to $5.42B over the twelve months to Sep 30, 2026. Operating income rose 335.2% to $383.00M, moving the operating margin from 1.8% to 7.1%. Free cash flow was $252.00M. At the latest close the market valued the company at $7.62B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $7.62B
- P/E ratio
- –
- Price to sales
- 1.41
- Price to book
- 1.18
- Dividend yield
- –
- Free cash flow yield
- 3.31%
Fundamentals
- Revenue
- $5.42B
- Net income
- -$111.00M
- EPS, diluted
- -$0.31
- Free cash flow
- $252.00M
- Book value per share
- $17.81
- Diluted shares
- 362M
Trading
- Next earnings
- Feb 17, 2027 (estimated, before the open)
- Previous close
- $21.37
- Open
- $21.36
- Day's range
- $21.08 – $21.38
- Volume
- 658,491
- Average volume (20 days)
- 1,044,240
- Beta (5 years)
- 0.76
- 52-week range
- $14.44 – $21.40
- RSI (14 days)
- 74.4
- Volatility (1 year)
- 33.0%
- Relative volume
- 1.17×
- WACC
- 7.6%
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | BLCO | S&P 500 | Difference | BLCO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +23.2% | -2.4% | +25.6 pts | ||
| 3 months | +26.4% | -1.2% | +27.5 pts | ||
| Year to date | +24.8% | +12.3% | +12.5 pts | ||
| 1 year | +29.8% | +12.4% | +17.3 pts | ||
| 3 years | +32.9% | +78.8% | −45.9 pts | +9.9% | +21.4% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Bausch & Lomb filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- News
- Results
- Results
- Results
About Bausch & Lomb
Ophthalmic Goods
Bausch + Lomb Corporation develops, manufactures, and markets eye health products worldwide across three operating segments: Vision Care, Pharmaceuticals, and Surgical. Its Vision Care unit provides contact lenses, including daily disposables and specialty lenses, as well as consumer eye care items such as lens care solutions, over-the-counter eye drops, and nutritional supplements. The Pharmaceuticals division offers prescription and generic medications for ocular conditions, including dry eye disease, glaucoma, ocular hypertension, and post-operative inflammation. The Surgical segment supplies ophthalmic surgical devices, diagnostic and procedural equipment, intraocular lenses, delivery systems, and surgical instruments. The company provides its products to patients, consumers, eye care professionals, optometrists, physicians, and retail partners.
Company profile, executives and historyBausch & Lomb stock: common questions
What is Bausch & Lomb's stock price?
BLCO closed at $21.32 on Nov 11, 2026, down 0.23% on the day. Over the past 52 weeks it traded between $14.44 and $21.40.
What is Bausch & Lomb's market cap?
Bausch & Lomb was worth $7.62B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is BLCO's P/E ratio?
Bausch & Lomb lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.31), so it has no meaningful P/E ratio.
How much revenue does Bausch & Lomb make?
Bausch & Lomb reported revenue of $5.42B for the twelve months to Sep 30, 2026, up 8.9% from a year earlier.
Does Bausch & Lomb pay a dividend?
No. Bausch & Lomb has not paid a cash dividend over the last twelve months.
When does Bausch & Lomb report earnings next?
Bausch & Lomb is expected to report Q4 FY2026 results on Feb 17, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has BLCO stock performed over the past year?
Including dividends, BLCO returned +29.8% over the past year, against +12.4% for the S&P 500.
How many BLCO shares are sold short?
3M shares were sold short at the latest FINRA report, 0.73% of the float, or 2.3 days of average trading volume.
Who are Bausch & Lomb's competitors?
Companies most similar to Bausch & Lomb by business, industry and size include ALC, COO, EYE, STAA, WRBY.
See a number that looks wrong?